{
    "doi": "https://doi.org/10.1182/blood.V114.22.4330.4330",
    "article_title": "Induction with New Drugs and Planned Autologous Followed by Non-Myeloablative Allogeneic Transplantation in Newly Diagnosed Myeloma. ",
    "article_date": "November 20, 2009",
    "session_type": "Clinical Results - Allogeneic Matched Related Donor Transplantation",
    "abstract_text": "Abstract 4330 Introduction Immunomodulatory drugs have recently changed the treatment options in multiple myeloma. Moreover, thalidomide, bortezomib and lenalidomide have also been used in the setting of allografting as post-transplant salvage therapy or as maintenance. We are currently evaluating the impact of new drugs as induction therapy in newly diagnosed multiple myeloma before a planned standard autograft followed by a non-myeloablative allograft (Tandem auto-allo). Patients and methods Twenty-five newly diagnosed patients (median age 55 years old, range 26-65) entered a recently designed prospective phase II program of tandem auto-allo which included the use of so-called new drugs during induction. Here, we report data on the first 11 evaluable patients with a follow up of at least 1 month after the allograft. Induction consisted of lenalidomide and dexamethasone (n=5), thalidomide and dexamethasone (n=4), or bortemomib-containing regimens (n=2), followed by G-CSF mobilized peripheral blood stem cell harvest. A standard autograft after melphalan 200 mg/m 2 was planned 2-4 months before a low-dose (2 Gy) TBI-based allograft from an HLA-identical sibling. GVHD prophylaxis consisted of cyclosporin and mycophenolate mofetil. Disease status at allografting and post-transplant outcomes were compared to those of 22 patients pair-matched for beta2microglobulin and age, who underwent tandem auto-allo after induction with VAD-based regimens without new drugs (Blood, 2009). Results At the time of allografting after induction with new drugs and the autograft overall response rate was 81% (9/11), including a immunofixation-negative complete remission (CR). Following allografting, all patients promptly achieved donor engraftment. After a median follow-up of 11 months (2-26), all patients are alive and the overall response rate was 91% (10/11). Incidence of grade II-IV GVHD was 34% (4/11), including 1 patient with grade III GVHD. Chronic GVHD was observed in 40% (4/10) of patients with at least 3 months of follow-up. The induction with new drugs did not increase allotransplant-related toxicity or incidence of acute GVHD (Table 1). We observed a higher response disease before allografting in patients treated with new drugs. Conclusions Induction with lenalidomide, thalidomide or bortezomib does not impact feasibility and safety of tandem auto-allo. Longer follow up and a larger cohort of patients are necessary to evaluate the impact of new drugs in improving disease control post-tandem auto-allo.  Induction . New drugs . No new drugs . No 11 22 ISS equal or higher than 2 3 6 Median age (range), years 55 (43-65) 52 (40-62) Disease status at allografting:   - Refractory disease 2 (18%) 6 (27%) - Partial response (PR) and very good PR 8 (73%) 15 (68%) - Complete remission 1 (9%) 1 (5%) Acute GVHD grade II/grade III-IV 3 (27%)/1 (9%) 6 (27%)/5 (23%) Induction . New drugs . No new drugs . No 11 22 ISS equal or higher than 2 3 6 Median age (range), years 55 (43-65) 52 (40-62) Disease status at allografting:   - Refractory disease 2 (18%) 6 (27%) - Partial response (PR) and very good PR 8 (73%) 15 (68%) - Complete remission 1 (9%) 1 (5%) Acute GVHD grade II/grade III-IV 3 (27%)/1 (9%) 6 (27%)/5 (23%) View Large Disclosures: Patriarca: Janssen Cilag: Honoraria; Celgene: Honoraria. Boccadoro: Celgene: Consultancy, advisory committees, Research Funding; Pharmion: Consultancy, advisory committees, Research Funding; Janssen Cilag: Consultancy, advisory committees, Research Funding.",
    "topics": [
        "multiple myeloma",
        "transplantation, homologous",
        "allografting",
        "allopurinol",
        "follow-up",
        "graft-versus-host disease",
        "lenalidomide",
        "thalidomide",
        "transplantation, autologous",
        "bortezomib"
    ],
    "author_names": [
        "Luisa Giaccone",
        "Moreno Festuccia",
        "Roberto Sorasio",
        "Nicola Mordini",
        "Fabrizio Carnevale Schianca",
        "Francesca Patriarca",
        "Marco Casini",
        "Anna Paola Iori",
        "Robin Foa\u0300",
        "Mario Boccadoro",
        "Benedetto Bruno"
    ],
    "author_dict_list": [
        {
            "author_name": "Luisa Giaccone",
            "author_affiliations": [
                "Divisione di Ematologia dell' Universita\u0300 di Torino, Azienda Ospedaliera S. Giovanni Battista di Torino, Torino, Italy, "
            ],
            "author_rank": 1,
            "first_author": 1,
            "last_author": 0
        },
        {
            "author_name": "Moreno Festuccia",
            "author_affiliations": [
                "Divisione di Ematologia dell' Universita\u0300 di Torino, Azienda Ospedaliera S. Giovanni Battista di Torino, Torino, Italy, "
            ],
            "author_rank": 2,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Roberto Sorasio",
            "author_affiliations": [
                "Divisione di Ematologia, Ospedale S. Croce e Carle di Cuneo, Cuneo, Italy, "
            ],
            "author_rank": 3,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Nicola Mordini",
            "author_affiliations": [
                "Divisione di Ematologia, Ospedale S. Croce e Carle di Cuneo, Cuneo, Italy, "
            ],
            "author_rank": 4,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Fabrizio Carnevale Schianca",
            "author_affiliations": [
                "Divisione Universitaria di Oncologia ed Ematologia, Istituto per la Ricerca e la Cura del Cancro, Candiolo, Italy, "
            ],
            "author_rank": 5,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Francesca Patriarca",
            "author_affiliations": [
                "Clinica Ematologica, Policlinico Universitario di Udine, Udine, Italy, "
            ],
            "author_rank": 6,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Marco Casini",
            "author_affiliations": [
                "Divisione di Ematologia, Azienda Ospedaliera Centro Sud, Bolzano, Italy, "
            ],
            "author_rank": 7,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Anna Paola Iori",
            "author_affiliations": [
                "Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy, "
            ],
            "author_rank": 8,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Robin Foa\u0300",
            "author_affiliations": [
                "Cattedra di Ematologia, Universita\u0300 La Sapienza, Roma, Italy"
            ],
            "author_rank": 9,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Mario Boccadoro",
            "author_affiliations": [
                "Divisione di Ematologia dell' Universita\u0300 di Torino, Azienda Ospedaliera S. Giovanni Battista di Torino, Torino, Italy, "
            ],
            "author_rank": 10,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Benedetto Bruno",
            "author_affiliations": [
                "Divisione di Ematologia dell' Universita\u0300 di Torino, Azienda Ospedaliera S. Giovanni Battista di Torino, Torino, Italy, "
            ],
            "author_rank": 11,
            "first_author": 0,
            "last_author": 1
        }
    ],
    "datetime_abstract_obtained": "2022-05-12T15:34:41",
    "is_scraped": "1"
}